Literature DB >> 25225246

Host immunity to Clostridium difficile PCR ribotype 017 strains.

Nazila V Jafari1, Mario Songane1, Richard A Stabler2, Mamoun Elawad3, Brendan W Wren2, Elaine Allan4, Mona Bajaj-Elliott5.   

Abstract

Clostridium difficile is an important nosocomial pathogen and the leading cause of antibiotic-associated diarrhea. Multilocus sequence typing indicates that C. difficile strains belong to five distinct genetic clades encompassing several PCR ribotypes (RT). Since their emergence in 2003, hypervirulent RT027 strains have been a major focus of research; in contrast, our current understanding of RT017-mediated disease pathogenesis lags far behind. In this study, we aimed to characterize host immunity to CF5 and M68, two genetically well-defined RT017 strains. Both strains engaged with host Toll-like receptor 2/6 (TLR2/6), TLR2-CD14, and TLR5 to similar extents in a model cell line. Despite this, CF5 mediated significantly greater dendritic cell (DC) interleukin-12 (IL-12), IL-27, and IL-10 immunity than M68. Both strains elicited similar IL-1β mRNA levels, and yet only M68 caused a marked increase in secretory IL-1β. A CF5 cocultured-DC cytokine milieu drove an equipotent Th1 and Th17 response, while M68 promoted greater Th17 immunity. Human gastrointestinal ex vivo cytokine responses to both strains were characterized. Taken together, our data suggest that C. difficile strains mediate overlapping and yet distinct mucosal and DC/T cell immunity. Finally, toxin-driven IL-1β release supports the hypothesis that this cytokine axis is a likely target for therapeutic intervention for C. difficile infection.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25225246      PMCID: PMC4249258          DOI: 10.1128/IAI.02605-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors:  Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

2.  Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts.

Authors:  Trevor D Lawley; Simon Clare; Alan W Walker; David Goulding; Richard A Stabler; Nicholas Croucher; Piero Mastroeni; Paul Scott; Claire Raisen; Lynda Mottram; Neil F Fairweather; Brendan W Wren; Julian Parkhill; Gordon Dougan
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

3.  International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants.

Authors:  Stuart Johnson; Susan P Sambol; Jon S Brazier; Michel Delmée; V Avesani; Michelle M Merrigan; Dale N Gerding
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia.

Authors:  Maja Rupnik; Naoki Kato; Miklavz Grabnar; Haru Kato
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen.

Authors:  Mizuho Hasegawa; Takashi Yamazaki; Nobuhiko Kamada; Kazuki Tawaratsumida; Yun-Gi Kim; Gabriel Núñez; Naohiro Inohara
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

6.  Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis.

Authors:  Irene Jarchum; Mingyu Liu; Lauren Lipuma; Eric G Pamer
Journal:  Infect Immun       Date:  2011-01-18       Impact factor: 3.441

7.  Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm.

Authors:  H Huang; H Fang; A Weintraub; C E Nord
Journal:  Clin Microbiol Infect       Date:  2009-07-15       Impact factor: 8.067

8.  Role of interleukin 23 signaling in Clostridium difficile colitis.

Authors:  Erica L Buonomo; Rajat Madan; Patcharin Pramoonjago; Li Li; Mark D Okusa; William A Petri
Journal:  J Infect Dis       Date:  2013-06-17       Impact factor: 5.226

9.  Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland.

Authors:  D Drudy; N Harnedy; S Fanning; R O'Mahony; L Kyne
Journal:  Clin Microbiol Infect       Date:  2007-03       Impact factor: 8.067

10.  Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile.

Authors:  S P Borriello; B W Wren; S Hyde; S V Seddon; P Sibbons; M M Krishna; S Tabaqchali; S Manek; A B Price
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

View more
  3 in total

1.  Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-κB Activity.

Authors:  Hon Wai Koon; Jiani Wang; Caroline C Mussatto; Christina Ortiz; Elaine C Lee; Diana Hoang-Ngoc Tran; Xinhua Chen; Ciaran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 2.  [Clostridium difficile infections in geriatric patients].

Authors:  R Simmerlein; A Basta; M Gosch
Journal:  Z Gerontol Geriatr       Date:  2016-10-26       Impact factor: 1.281

Review 3.  Host Immune Responses to Clostridioides difficile: Toxins and Beyond.

Authors:  Britt Nibbering; Dale N Gerding; Ed J Kuijper; Romy D Zwittink; Wiep Klaas Smits
Journal:  Front Microbiol       Date:  2021-12-21       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.